In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 47 days of free consultation

 

Causes of death within the first year after transcatheter aortic valve implantation: Lessons from EVERY-TAVI registry

Session Poster Session 6

Speaker Nicole Karam

Congress : ESC Congress 2019

  • Topic : valvular, myocardial, pericardial, pulmonary, congenital heart disease
  • Sub-topic : Valvular Heart Disease: Intervention
  • Session type : Poster Session
  • FP Number : P5584

Authors : N Karam (Paris,FR), D Jochheim (Munich,DE), M Zadrozny (Munich,DE), JM Fischer (Munich,DE), S Gschwender (Munich,DE), D Grundmann (Munich,DE), M Baquet (Munich,DE), A Bauer (Munich,DE), H Theiss (Munich,DE), C Hagl (Munich,DE), M Pichlmeier (Munich,DE), S Massberg (Munich,DE), J Mehilli (Munich,DE)

Authors:
N Karam1 , D Jochheim2 , M Zadrozny2 , JM Fischer2 , S Gschwender2 , D Grundmann2 , M Baquet2 , A Bauer2 , H Theiss2 , C Hagl3 , M Pichlmeier3 , S Massberg2 , J Mehilli2 , 1Inserm U970 - Paris Cardiovascular Research Center (PARCC), Cardiovascular Epidemiology-Sudden Death - Paris - France , 2University Hospital of Munich, Cardiology - Munich - Germany , 3University Hospital of Munich, Cardiac surgery - Munich - Germany ,

Citation:

Background:According to current recommendations, transcatheter aortic valve implantation (TAVI) should only be performed among patients with a life expectancy of at least one year. However, many deaths occur within the first year after TAVI. 
Purpose:To assess the causes of death within one year after TAVI.
Methods:Data was taken between November 2007 and December 2017 from the EVERY-TAVI registry. Patients who died during TAVI or experienced mechanical complications requiring surgery were excluded from the analysis. We assessed the causes of death over 3 periods post-TAVI: within the first 30 days, between 30 and 90 days, and between 90 and 365 days.
Results:Overall, 2389 patients underwent TAVI without mechanical complications. Among them, 320 (1.3%) died within one year. Age was the main cause of death, accounting for 73 deaths (22.8%), followed by heart failure (20.6%) and infections (18.7%). During the first month, cardiogenic shock was the main cause of death (25.4%), followed by infections (22.2%) and terminal heart failure (20.6%), while age was responsible of only one death (1.6%). During the two following months, heart failure was the main cause of death (33.3%), followed by infections (21.2%), and the percentage of deaths due to age increased to 18.2%. After 3 months, age was the main cause of death (31.4%), followed by infection (16.8%) and heart failure (16.2%).
Conclusion:Cardiogenic shock is the main cause within the first month after TAVI, while older age is the main cause overall and after the initial months, highlighting the need to more carefully selection of patients undergoing TAVI.

Cause of death

All

n=320

< 30 days

n=63

30-90 days

n=66

> 90 days

n=191

Older age, n(%)

73 (22.8)

1 (1.6)

12 (18.2)

60 (31.4)

Terminal heart failure, n(%)

66 (20.6)

13 (20.6)

22 (33.3)

31(16.2)

Infection, n(%)

60 (18.7)

14 (22.2)

14 (21.2)

32 (16.8)

Terminal renal failure, n(%)

26 (8.1)

4 (6.3)

5 (7.6)

17 (8.9)

Cardiogenic shock, n(%)

26 (8.1)

16 (25.4)

4 (6.1)

6 (3.1)

Malignancies, n(%)

18 (5.6)

0 (0.0)

2 (3.0)

16 (8.4)

Sudden death, n(%)

17 (5.3)

6 (9.5)

2 (3.0)

9 (4.7)

Stroke, n(%)

12 (3.7)

4 (6.3)

2 (3.0)

6 (3.1)

Accident, n(%)

7 (2.2)

2 (3.2)

0 (0.0)

5 (2.6)

Myocardial infarction, n(%)

7 (2.2)

2 (3.2)

2 (3.0)

3 (1.6)

Non-cardiac surgery, n(%)

5 (1.6)

1 (1.6)

1 (1.5)

3 (1.6)

Pulmonary embolism, n(%)

3 (0.9)

0 (0.0)

0 (0.0)

3 (1.6)

This content is currently on FREE ACCESS, enjoy another 47 days of free consultation

 



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are